Drug
Ipn60300
Ipn60300: highest development phase Phase 1/2, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| IPN60300 NCT07213817 | Phase 1/2 | Locally Advanced Solid Tumor |
Latest
No recent events.
Follow Ipn60300 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.